目的探讨SOX、CapeOX、mFOLFOX6三种化疗方案在进展期胃癌治疗中的临床疗效及患者的不良反应和耐受性,以期为临床化疗方案的选择提供参考。方法选取2014年5月至2016年5月住院治疗的84例进展期胃癌患者为研究对象,按随机数字表法分为三组各28例,SOX组接受奥沙利铂+替吉奥胶囊治疗,CapeOX组接受奥沙利铂+卡培他滨治疗,mFOLFOX6组接受奥沙利铂+亚叶酸钙+5-氟尿嘧啶治疗。观察三组患者治疗过程的耐受情况,比较治疗后的临床疗效和不良反应。统计学检验水准取α=0.05,采用χ2检验分割法时,检验水准校正为α’=0.017。结果 84例患者中71例顺利完成治疗,SOX组、CapeOX组、m FOLFOX6组患者对化疗的耐受率分别为89.29%、85.71%、78.57%,组间差异无统计学意义(P>0.05);三组治疗总有效率分别为52.00%、41.67%、36.36%,组间差异无统计学意义(P>0.05)。治疗过程的不良反应中,细胞毒性、神经毒性(以Ⅰ~Ⅱ度为主)发生率三组间无统计学差异(P均>0.05);SOX组和mFOLFOX6组的手足综合征发生率分别低于CapeOX组(P均<0.017),SOX组和CapeOX组恶心呕吐的发生率分别低于mFOLFOX6组(P均<0.017)。结论进展期胃癌患者对SOX、CapeOX、m FOLFOX6三种化疗方案的耐受性相当,但SOX方案的疗效略高于其他两种,不良反应相对较轻,且用药方便,更适合患者。 Objective To investigate the clinical efficacy of SOX, CapeOX and mFOLFOX6 chemotherapy in patients with advanced gastric cancer and the adverse reactions and tolerability of the three chemotherapy regimens in order to provide a reference for the choice of clinical chemotherapy regimen. Methods Eighty-four patients with advanced gastric cancer hospitalized in our hospital from May 2014 to May 2016 were selected and divided into three groups of 28 patients according to random number table. SOX group received oxaliplatin + , CapeOX group received oxaliplatin + capecitabine treatment, mFOLFOX6 group received oxaliplatin + leucovorin + 5-fluorouracil treatment. To observe the three groups of patients during the treatment of tolerance, compare the clinical efficacy and adverse reactions after treatment. Statistics test level take α = 0.05, using χ2 test segmentation method, the test level correction is α ’= 0.017. Results 71 of the 84 patients were successfully treated. The tolerability rate of chemotherapy in SOX group, CapeOX group and m FOLFOX6 group was 89.29%, 85.71% and 78.57%, respectively. There was no significant difference between the two groups (P> 0.05) The total effective rates of the three groups were 52.00%, 41.67% and 36.36% respectively. There was no significant difference between the two groups (P> 0.05). There were no significant differences in the incidence of cytotoxicity and neurotoxicity (mainly Ⅰ ~ Ⅱ degree) between the three groups (P> 0.05). The incidence of hand-foot syndrome in SOX group and mFOLFOX6 group was significantly lower In the CapeOX group (all P <0.017), the incidences of nausea and vomiting in the SOX and CapeOX groups were significantly lower than those in the mFOLFOX6 group (all P <0.017). Conclusions Patients with advanced gastric cancer are equally tolerant to SOX, CapeOX and m FOLFOX6 chemotherapy. However, the efficacy of SOX is slightly higher than that of the other two. The adverse reactions are relatively mild and the medication is convenient and suitable for patients.